Tokumitsu, Keita
Sugawara, Norio
Maruo, Kazushi
Suzuki, Toshihito
Shimoda, Kazutaka
Yasui-Furukori, Norio
Funding for this research was provided by:
Japan Society for the Promotion of Science (15H04754)
Article History
Received: 24 September 2019
Accepted: 11 June 2020
First Online: 26 June 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Norio Yasui-Furukori has been a speaker for Dainippon-Sumitomo Pharmaceutical, Mochida Pharmaceutical, and MSD. Kazutaka Shimoda has received research support from Meiji Seika Pharma Co., Pfizer Inc., Dainippon Sumitomo Pharma Co., Ltd., Daiichi Sankyo Co., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Novartis Pharma K.K., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. and honoraria from Mitsubishi Tanabe Pharma Corporation, Meiji Seika Pharma Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Shionogi & Co., Ltd., Daiichi Sankyo Co., Pfizer Inc. and Eisai Co., Ltd. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript. The remaining authors declare that they have no competing interests to report.